Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

NCT06997276 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Hepatic Impairment

Interventions

DRUG: Mirdametinib (MEK Inhibitor)

Sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany